Boston, MA 09/30/2014 (wallstreetpr) – Healthcare services company, Cardinal Health Inc (NYSE:CAH) and the private held KEW Group, Inc. disclosed that they have struck an agreement to make available KEW’s high-tech diagnostic services to customers of Specialty Solutions’ community oncology.
Access To KEW Facility
The Cardinal Health Inc (NYSE:CAH) indicated that as a result of its agreement with KEW Group, Specialty Solutions customers would be able to gain access to CancerPlexSM of KEW, which provided highly comprehensive and versatile genetic test offering minute, timely and thorough molecular patients’ diagnosis of solid tumor, its statement revealed. This would also provide oncologists the knack to manage the patients’ treatments decision as a result of accurate, personalized medicine.
CancerPlex also simultaneously offers a comprehensive coverage of over 410 cancer genes apart from simplifying and streamlining the process of test-ordering by removing serial hotspot tests. Aside from these, it also delivers a complete report of actionable data and keeps physicians informed of maximum options of treatment by using approved therapies along with the available clinical trials. It also helps the enrollment for clinical trial by offering oncologists with the necessary molecular data.
Management Comments
Cardinal Health Inc (NYSE:CAH) Specialty Solution’s Senior VP of Clinical Services, Scott Howell, said that the company was committed to working with everyone concerned in the healthcare system to make sure that right patients get the treatment at the right time. He said that its expanded deal with KEW Group would allow the company to deliver the commitment by offering community oncologists with entry to high-tech diagnostic tools, which could help them, make the most and best informed decisions of treatment for their patients. At the same time, he indicated that care would be taken to improve the overall effectiveness of the costs involved.
Similarly, KEW Group CEO, Scott Schell, said that the company was excited to make available its leading-edge molecular diagnostics tools to community oncologists throughout the nation with the help of Cardinal Health Inc (NYSE:CAH) Specialty Solutions.
